Bright Minds Biosciences Inc. (DRUG) Income Statement
DRUG FY2025 at a glance
Fiscal year ended September 30, 2025 · Canadian dollarsDRUG revenue and net income
DRUG growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
DRUG income statement in Canadian dollars
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 |
| Cost of revenue | C$55,191 | — | C$72,450 | C$6,037 | — | — | — |
| Gross profit | −C$76,976 | — | −C$72,450 | −C$6,037 | — | — | — |
| Research & development | C$11.1M | C$1.2M | C$5.0M | C$12.2M | C$6.3M | C$354,852 | C$126,027 |
| Sales, general & admin | C$2.6M | C$1.4M | C$2.2M | C$2.6M | C$2.3M | C$114,506 | C$110,124 |
| Total operating expenses | C$13.9M | C$2.8M | C$7.4M | C$15.0M | C$8.6M | C$469,358 | C$236,151 |
| Operating income | −C$13.9M | −C$2.8M | −C$7.4M | −C$15.0M | −C$8.8M | −C$469,358 | −C$236,151 |
| Interest income | C$1.5M | C$30,133 | C$0 | C$0 | — | — | — |
| Interest expense | C$25,741 | — | C$19,750 | C$222,777 | C$0 | C$0 | C$0 |
| Income before taxes | −C$12.2M | −C$2.8M | −C$7.4M | −C$15.0M | −C$8.7M | −C$480,377 | −C$236,151 |
| Income taxes | — | — | −C$14,189 | C$222,777 | −C$135,434 | C$5,568 | −C$236 |
| Net income | −C$12.2M | −C$2.8M | −C$7.4M | −C$15.0M | −C$8.5M | −C$485,945 | −C$236,151 |
| EBITDA | −C$12.2M | −C$2.7M | −C$7.3M | −C$15.0M | −C$8.8M | −C$469,358 | −C$78,720 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 |
| Cost of revenue | C$19,973 | C$20,130 | C$19,772 | C$12,212 | C$11,638 | — | — | — | C$18,113 | C$18,112 | C$18,113 | C$18,112 |
| Gross profit | −C$19,973 | −C$20,130 | −C$19,772 | −C$12,212 | −C$11,638 | — | — | — | −C$18,113 | −C$18,112 | −C$18,113 | −C$18,112 |
| Research & development | C$9.5M | C$13.3M | C$5.7M | C$4.8M | C$2.7M | C$2.6M | C$1.0M | C$416,055 | C$566,749 | C$105,180 | C$1.2M | C$1.1M |
| Sales, general & admin | C$2.2M | C$2.2M | C$1.1M | C$756,405 | C$591,936 | C$676,160 | C$540,928 | C$351,012 | C$320,644 | C$432,644 | C$401,181 | C$459,164 |
| Total operating expenses | C$11.7M | C$15.5M | C$6.9M | C$5.7M | C$3.3M | C$3.4M | C$1.6M | C$791,310 | −C$234,742 | C$558,062 | C$1.7M | C$1.6M |
| Operating income | −C$11.7M | −C$15.6M | −C$6.9M | −C$5.7M | −C$3.3M | −C$3.4M | −C$1.6M | −C$791,310 | C$234,742 | −C$558,062 | −C$1.7M | −C$1.6M |
| Interest income | C$2.8M | C$2.7M | C$818,265 | C$529,538 | C$476,231 | C$509,381 | C$4,318 | C$6,007 | C$14,987 | C$0 | — | — |
| Interest expense | C$4,174 | C$5,592 | C$6,572 | — | — | — | — | — | C$1,241 | C$2,126 | C$2,971 | C$3,786 |
| Income before taxes | −C$2.5M | −C$10.6M | −C$7.6M | −C$4.1M | −C$5.2M | −C$3.0M | C$49,610 | −C$773,441 | C$229,903 | −C$574,141 | −C$1.7M | −C$1.5M |
| Income taxes | — | — | — | C$185,149 | — | — | — | — | −C$4 | −C$2 | −C$14,731 | −C$57,934 |
| Net income | −C$2.5M | −C$10.6M | −C$7.6M | −C$4.1M | −C$5.2M | −C$3.0M | C$49,610 | −C$773,441 | C$229,903 | −C$574,141 | −C$1.7M | −C$1.5M |
| EBITDA | −C$11.7M | −C$10.6M | −C$7.5M | −C$4.1M | −C$5.2M | −C$3.3M | C$71,143 | −C$754,422 | C$248,016 | −C$556,029 | −C$1.7M | C$22,481 |
Quarterly columns are labeled by the month the quarter ended. Figures in Canadian dollars as reported in DRUG's financial statements (latest annual report filed December 23, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
DRUG financial results
Bright Minds Biosciences reported no revenue in fiscal year 2025 (ended September 30, 2025). It had a net loss of C$12.2 million. Figures are in Canadian dollars, the currency of its financial statements.
See the DRUG stock overview for the latest quote and news, or the DRUG chart for price history and technical indicators.
DRUG income statement FAQ
Does Bright Minds Biosciences have revenue?
Bright Minds Biosciences reported no revenue for fiscal year 2025, which ended on September 30, 2025.
Is Bright Minds Biosciences profitable?
No. Bright Minds Biosciences reported a net loss of C$12.2 million in fiscal 2025.
How much does Bright Minds Biosciences spend on research and development?
Bright Minds Biosciences spent C$11.1 million on research and development in fiscal 2025.
When does Bright Minds Biosciences's fiscal year end?
Bright Minds Biosciences's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on December 23, 2025.